<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005573</url>
  </required_header>
  <id_info>
    <org_study_id>DRGS-2014-2015-165-2</org_study_id>
    <nct_id>NCT04005573</nct_id>
  </id_info>
  <brief_title>The Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Lipid Profile Levels and Oxidized Low Density Lipoprotein</brief_title>
  <official_title>Assessing the Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Lipid Profile Levels and Oxidized Low Density Lipoprotein: a Randomized Controlled Trial in Males and Females With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Science Private University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Science Private University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined effect of omega-3 fatty acid and vitamin D3 on lipid profile levels and oxidized
      low density lipoprotein: a randomized controlled trial in males and females with vitamin D
      deficiency
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nothing is published in the literature about the combined effect of vitamin D3 (VD3) and
      omega-3 fatty acids (omega-3FA) on on lipid profile levels and oxidized low density
      lipoprotein

      This study will be conducted to investigate effect of VD3 and omega-3FA alone and with each
      other on lipid profile levels and oxidized low density lipoprotein in Jordanian people with
      vitamin D deficiency.

      This randomized, controlled clinical trial will be designed to test effects of 50,000 IU VD3
      weekly and 300 mg omega-3FA daily for eight weeks, separately and with each other, on on
      lipid profile levels and oxidized low density lipoprotein
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VD 3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum level of 25-hydroxyvitamin D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of total cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of HDL Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of LDL Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>triglycerides</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of triglycerides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxidized LDL</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of oxidized LDL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium and Phosphorus</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of Calcium and Phosphorus</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>VD3 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3- FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VD3 and omega 3 FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>no intervention was given</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3</intervention_name>
    <description>VD3 50000 IU/ week for 8 weeks</description>
    <arm_group_label>VD3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega 3- FA</intervention_name>
    <description>Omega 3 FA group 300 mg once daily for 8 weeks</description>
    <arm_group_label>omega 3- FA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3 and omega- 3FA</intervention_name>
    <description>50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks</description>
    <arm_group_label>VD3 and omega 3 FA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention is given</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Jordanian people aged 25-55 medical diagnosis of vitamin D deficiency ( VD &lt;25 ng/ ml)

        Exclusion Criteria:

          -  Subjects with previously diagnosed with any chronic disease (cardiovascular disease,
             osteoporosis, cancer, kidney disease, endocrine disorder, thalassemia) or has a
             documented history of allergic reactions to n-3FA supplementations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud S Abu-Samak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied science university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Applied Science University</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <reference>
    <citation>Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012 Jan;33(1):159-71. doi: 10.1016/j.cct.2011.09.009. Epub 2011 Oct 2.</citation>
    <PMID>21986389</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>oxidized low density Lipoprotein</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underline results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>when summary data will published</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

